Every open market buy and sale of Bicara Therapeutics Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are net sellers over the last 12 months: $4.8M bought and $9.9M sold.
Buying and selling by month
open market, last 12 monthsGet an alert when BCAX insiders trade
We read every Form 4 the moment the SEC posts it and tell you when an BCAX officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.
Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.
Every BCAX insider trade
2 years · newest first| Insider | Type | Price | Held after | Filed | |||
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Ryan CohlheppPresident, COO & Interim CEO | Sale plan | 17,500 | $22.90 | $401K | 181,641 | Sep 10Form 4 |
| Aug 10, 2026 | Ryan CohlheppPresident and COO | Sale plan | 18,750 | $27.98 | $525K | 181,641 | Aug 12Form 4 |
| Aug 10, 2026 | Claire MazumdarCEO | Sale plan | 10,000 | $27.98 | $280K | 362,152 | Aug 12Form 4 |
| Aug 10, 2026 | Ivan HyepCFO | Sale plan | 12,500 | $27.97 | $350K | 129,855 | Aug 12Form 4 |
| Jul 10, 2026 | Claire MazumdarCEO | Sale plan | 10,000 | $28.42 | $284K | 362,152 | Jul 14Form 4 |
| Jul 9, 2026 | Ryan CohlheppPresident and COO | Sale plan | 28,750 | $28.98 | $833K | 181,641 | Jul 10Form 4 |
| Jul 8, 2026 | Ivan HyepCFO | Sale plan | 28,000 | $28.85 | $808K | 129,855 | Jul 10Form 4 |
| May 21, 2026 | Ivan HyepCFO | Sale plan | 9,200 | $20.42 | $188K | 145,355 | May 26Form 4 |
| May 18, 2026 | Claire MazumdarCEO | Sale plan | 15,000 | $20.04 | $301K | 362,152 | May 20Form 4 |
| May 15, 2026 | Ryan CohlheppPresident and COO | Sale plan | 12,500 | $20.29 | $254K | 191,641 | May 18Form 4 |
| Apr 27, 2026 | David RabenChief Medical Officer | Sale plan | 5,500 | $22.88 | $126K | 55,286 | Apr 28Form 4 |
| Apr 21, 2026 | Ivan HyepCFO | Sale plan | 9,200 | $23.00 | $212K | 145,355 | Apr 22Form 4 |
| Apr 20, 2026 | Claire MazumdarCEO | Sale plan | 15,000 | $23.61 | $354K | 362,152 | Apr 20Form 4 |
| Apr 15, 2026 | Ryan CohlheppPresident and COO | Sale plan | 12,500 | $23.01 | $288K | 196,141 | Apr 17Form 4 |
| Mar 25, 2026 | David RabenChief Medical Officer | Sale plan | 5,500 | $18.95 | $104K | 55,286 | Mar 26Form 4 |
BCAX insider trading FAQ
Are BCAX insiders buying or selling?
Insiders are net sellers over the last 12 months. 1 insiders bought $4.8M of BCAX on the open market in 1 trades, and 4 sold $9.9M in 33 trades, 100% of that under pre-arranged trading plans.
When did an BCAX insider last buy shares?
Ra Capital Management, L.P. (Director) bought 300,000 shares for $4.8M on Feb 26, 2026, reported on Mar 2, 2026.
When did an BCAX insider last sell shares?
Ryan Cohlhepp (President, COO & Interim CEO) sold 17,500 shares for $401K on Sep 8, 2026, under a pre-arranged trading plan.
What is a Form 4?
Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.
Why do insider sales matter less than buys?
Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.
From SEC Form 4 filings · Not investment advice
